Esthesioneuroblastoma

Source: Wikipedia, the free encyclopedia.
Esthesioneuroblastoma
Other namesNeuroblastoma
Esthesioneuroblastoma
SpecialtyNeuro-oncology

Esthesioneuroblastoma is a rare cancer of the nasal cavity. Arising from the upper nasal tract, esthesioneuroblastoma is believed to originate from sensory neuroepithelial cells, also known as neuroectodermal olfactory cells.[1]

Due to the location of the tumor and its proximity to the cranial cavity, esthesioneuroblastoma can be highly invasive and challenging to treat. There is no consensus on an appropriate treatment approach of esthesioneuroblastoma because of the rarity of the disease. Most studies reported cranial surgical resection with radiotherapy or chemotherapy to target the tumor.[2]

Signs and symptoms

Esthesioneuroblastoma frequently first presents as a nasal mass.

oral cavity, there can be tooth pain and tooth mobility.[6]

Genetics

There is limited research on the genetic role in esthesioneuroblastoma development. Of the research to date, the

sonic hedgehog pathway, MYC and KDR genes are implicated for esthesioneuroblastoma.[7][8]

Mutations in

LAMA2) have also been implicated in this disease.[9]

Pathophysiology

Esthesioneuroblastoma is of neurocrest origin, arising from olfactory sensory cells in the

basal cells.[1] Esthesioneuroblastoma consists of lobular sheets with neurofibrullar fibers and rosettes.[4] Hyam's classifications are an important way of determining prognosis.[10]

Hyam's histopathological grades for esthesioneuroblastoma[11]

Grade Lobular architexture preservation Mitotic index Nuclear polymorphism Fibrillary matrix Rosettes Necrosis
I + none none prominent
Homer Wright (HW) rosettes
 none
II + low moderate present HW rosettes none
III +/- moderate prominent low
Flexner-Wintersteiner rosettes
 rare
IV +/- high marked absent none frequent

Diagnosis

Esthesioneuroblastoma can resemble small blue cell tumors like

S-100 protein or NSE can be run to further differentiate esthesioneuroblastoma from other tumors.[1]

Staging

The Kadish classification is used for clinical classification of sinonasal tumors including esthesioneuroblastoma. Subsequent research articles have been published to determine prognosis based on tumor grade.

Modified Kadish classification[13][4]

Stage Description 5 year survival
A Tumor confined to nasal cavity 75–91
B Nasal cavity and paranasal sinuses 68–71
C Tumor extends beyond nasal cavity and paranasal sinuses, including skull base, orbit or cribiform plate 41–47
D Tumor metastasizes to cervical lymph nodes and beyond <40

Dulguerov classification[14]

Stage Characteristics
T1 Tumour involving the
ethmoidal cells
T2 Tumour involving the nasal cavity and/or paranasal sinuses (including the sphenoid) with extension to or erosion of the cribriform plate
T3 Tumour extending into the orbit or protruding into the anterior cranial fossa, without dural invasion
T4 Tumour involving the brain
N0 No cervical lymph-node metastasis
N1 Any form of cervical lymph-node metastasis
M0 No metastases
M1 Distant metastasis

Treatment

The preferred treatment for esthesioneuroblastoma is surgery followed by

radiotherapy to prevent recurrence of the tumor.[14]

Surgical approaches

Several surgical approaches have been described,

orbital periosteum.[14]

Radiotherapy

Radiotherapy alone is reserved only for small lesions not appropriate for either surgery or chemotherapy.[4] Both photon and proton radiotherapy have been used effectively to treat esthesioneuroblastoma.[14][21] Proton radiotherapy has recently been shown to be effective in a 10-person study with Kadish C tumors, while delivering less toxicity to the nervous system.[21]

Chemotherapy

Chemotherapy is used in a multimodality treatment plan generally for more advanced, unresectable or reoccurring tumors.[4] Cyclophosphamide, vincristine and doxorubicin have been used as neoadjuvant chemotherapy drugs for grade C esthesioneuroblastoma before surgical resection, producing fair outcomes. Cisplatin and etoposide are often used to treat esthesioneuroblastoma as neoadjuvants or adjuvants with radiotherapy or surgery.[22][23][24]

Study results are promising. In advanced stage esthesioneuroblastoma in pediatric patients, where surgery is no longer possible, aggressive chemotherapy and radiotherapy has resulted in some tumor control and long-term survival.[25]

Prognosis

Esthesioneuroblastoma is a slow developing but malignant tumor with high recurrence rates because of its anatomical position.

cerebral spinal fluid unlike patients with low grade tumors who usually only see local recurrence.[26]

Survival rates for treated esthesioneuroblastoma are best for surgery with radiotherapy (65%), then for radiotherapy and chemotherapy (51%), just surgery (48%), surgery, radiotherapy and chemotherapy (47%) and finally just radiotherapy (37%).[14] From the literature, radiotherapy and surgery seem to boast the best outcome for patients. However, it is important to understand that to some degree, prognosis is related to tumor severity. More progressed, higher grade tumors would result in chemotherapy or radiotherapy as the only treatment. It is no surprise that the prognosis would be worse in these cases.[citation needed]

Incidence

Esthesioneuroblastoma accounts for 2% of all intranasal tumors with an incidence of 0.4 cases per million people.[1] Fewer than 700 cases have been documented in the United States.[12] Fewer than 400 unique cases have been reported globally.[4][1] Esthesioneuroblastoma can occur at any time, with peak occurrence reported in the second and sixth decades of life.[1]

History

Esthesioneuroblastoma was first characterized in 1924.[27][28]

Notable cases

The disease was brought into prominence by the case of Chantal Sébire, who was suffering from the disease and ended her life after being denied euthanasia.[29]

References

  1. ^ a b c d e f g h i j k Thompson LD (2009). Olfactory neuroblastoma. Head and neck pathology. 3: 252–259
  2. S2CID 9860811
    .
  3. S2CID 20079359
    .
  4. ^ a b c d e f g Sheehan JM (2011). "Esthesioneuroblastoma". In Jane JA (ed.). Youmans Neurological Surgery (6th ed.). Retrieved 7 December 2016.
  5. PMID 16119902
    .
  6. PMID 24443792
    .
  7. S2CID 33078469
    .
  8. PMID 22649506
    .
  9. PMID 30575736
    .
  10. ^
    PMID 23266076
    .
  11. ^ Hyams VG, Baksakis JG, Michaels L, eds. (1988). Tumors of the upper respiratory tract and ear. Washington DC: Armed Forces Institute of Pathology. pp. 240–248.
  12. ^
    S2CID 41961725
    .
  13. PMID 1260676
    .
  14. ^
    PMID 11902539
    .
  15. PMID 26614835
    .
  16. PMID 17571044
    .
  17. S2CID 13035634
    .
  18. PMID 12090952
    .
  19. S2CID 27445039
    .
  20. ^
    PMID 3138210
    .
  21. ^
    PMID 19240832
    .
  22. S2CID 25788460
    .
  23. PMID 9006501
    .
  24. S2CID 44518377
    .
  25. PMID 22443159
    .
  26. PMID 23312882
    .
  27. ^ Fordice JO (3 March 1994). "Esthesioneuroblastoma". Baylor College of Medicine. Archived from the original on April 9, 2007. Retrieved 2008-03-22.
  28. ^ Berger L, Luc G, Richard D (1924). "L'esthésioneuroépithéliome olfactif". Bull Assoc Franç Étude Cancer. 13: 410–421.
  29. ^ "BBC NEWS - Europe - Tumour woman's death not natural". BBC. 21 March 2008. Retrieved 1 November 2016.

External links

Retrieved from "https://en.wikipedia.org/w/index.php?title=Esthesioneuroblastoma&oldid=1190107446"